HOOKIPA bags US$10m cancer milestone
HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.
Cambridge-based endovascular surgical AI specialist Cydar Medical has completed a 10.5m (£9.3m) Series A funding round led by Pembroke Venture Capital Trust
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
South Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BVs propietary ADC platform.
A new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
British researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
A new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
British researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters